CEMI - Chembio Diagnostics, Inc.
7.09 0.00 (0.00%)
After hours: 4:00PM EDT
| Previous Close | 7.34 |
| Open | 7.33 |
| Bid | 5.59 x 1100 |
| Ask | 7.94 x 800 |
| Day's Range | 7.00 - 7.56 |
| 52 Week Range | 4.85 - 11.55 |
| Volume | 42,116 |
| Avg. Volume | 74,503 |
| Market Cap | 121.71M |
| Beta (3Y Monthly) | 1.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.65 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.50 |
- GlobeNewswire•17 days ago
Chembio Diagnostics Announces Approval of Dengue Point-of-Care Test by Brazil’s Health Regulatory Agency
Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the approval of its DPP Dengue System by Agência Nacional de Vigilância Sanitária (ANVISA), Brazil’s health regulatory agency, in collaboration with Bio-Manguinhos, a Brazilian government agency and supplier of diagnostic products to Brazil’s Ministry of Health. Chembio’s DPP Dengue test allows simultaneous and discrete detection of antibodies against all four dengue serotypes for both active infection by dengue virus (IgM) and prior exposure to the dengue virus (IgG), which is important for both treatment and surveillance.
- Thomson Reuters StreetEvents•18 days ago
Edited Transcript of CEMI earnings conference call or presentation 1-May-19 8:30pm GMT
Q1 2019 Chembio Diagnostics Inc Earnings Call
- GlobeNewswire•22 days ago
Chembio Diagnostics Reports First Quarter 2019 Financial Results
MEDFORD, N.Y., May 01, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial.
- Simply Wall St.•24 days ago
Introducing Chembio Diagnostics (NASDAQ:CEMI), The Stock That Zoomed 142% In The Last Five Years
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The worst result, after buying shares in a company (assuming no leverage), would be if you lose all...
- GlobeNewswire•last month
Chembio Diagnostics to Report First Quarter 2019 Financial Results on May 1, 2019
Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the first quarter of 2019 after the close of trading on Wednesday, May 1, 2019. Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. The company’s patented DPP technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in approximately 15 minutes.
- GlobeNewswire•last month
Chembio Diagnostics Announces Approval of Zika, Dengue and Chikungunya Point-of-Care Multiplex Test by Brazil’s Health Regulatory Agency
Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the approval of its DPP Zika/Dengue/Chikungunya System by Agência Nacional de Vigilância Sanitária (ANVISA), Brazil’s health regulatory agency, in collaboration with Bio-Manguinhos/Fiocruz. Chembio’s DPP Zika/Dengue/Chikungunya multiplex test allows simultaneous and discrete detection of antibodies for both active (IgM) and prior exposure (IgG) to the Zika, dengue, and chikungunya viruses, which is important for both treatment and surveillance. The test is performed using a small (10µL) drop of fingertip blood and provides quantitative results in approximately 15 minutes when used with the company’s handheld DPP Micro Reader.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of CEMI earnings conference call or presentation 7-Mar-19 9:30pm GMT
Q4 2018 Chembio Diagnostics Inc Earnings Call
- GlobeNewswire•2 months ago
Chembio Diagnostics Announces Agreement with Perseus Science to Advance Point-of-Care Concussion Test
Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that the company has entered into an agreement with Perseus Science Group LLC, to advance the development of a diagnostic test for mild traumatic brain injury (TBI), or concussion. This agreement builds on previous agreements between the two firms that resulted in the completion of technical feasibility to detect Perseus’ patented biomarker. Under terms of this agreement, Chembio will receive funding from Perseus, subject to satisfying certain milestones, to advance the development of a quantitative point-of-care test for concussion, combining Chembio's proprietary DPP platform with Perseus’ biomarker.
- Zacks Small Cap Research•2 months ago
CEMI: Revenue, margin guidance and historical context indicates this could be opportune entry point
Chembio (CEMI) reported financial results for their fourth quarter ending December 31st and provided an operating update. Product sales were just about dead-on with our estimate and up 16% yoy to $5.6M. Total revenue jumped 27% to $7.6M, aided by a very healthy $1.7M in R&D contracts, milestones and grant revenue – which is the greatest quarterly revenue from this category in company history.
- GuruFocus.com•2 months ago
Chembio Diagnostics Inc (CEMI) Files 10-K for the Fiscal Year Ended on December 31, 2018
Chembio Diagnostics Inc develops, manufactures, and commercializes point of care diagnostic tests that detect infectious diseases. Warning! GuruFocus has detected 4 Warning Signs with CEMI. For the last quarter Chembio Diagnostics Inc reported a revenue of $7.60 million, compared with the revenue of $5.99 million during the same period a year ago.
- Simply Wall St.•2 months ago
Have Insiders Been Buying Chembio Diagnostics, Inc. (NASDAQ:CEMI) Shares?
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be remiss not to mention that insider sales haveRead More...
- GlobeNewswire•3 months ago
Chembio Diagnostics Reports Fourth Quarter and Full Year 2018 Financial Results
MEDFORD, N.Y., March 07, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial.
- GlobeNewswire•3 months ago
Chembio Diagnostics Awarded UNICEF Contract to Supply Point-of-Care Zika/Chikungunya/Dengue Tests and Micro Readers
Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today announced that it will be awarded a conditional Long Term Arrangement (LTA) from UNICEF for purchases of the company’s DPP® Zika/Chikungunya/Dengue System. The UNICEF LTA, which is valid through December 31, 2020, includes a firm purchase commitment of $1.5 million and possible additional purchases of up to $2.0 million, for a total amount of up to $3.5 million. All of the purchases are subject to Chembio meeting the following conditions: receipt of CE mark certification, completion of clinical and analytical performance evaluation, and a successful quality management system (QMS) inspection.
- GlobeNewswire•3 months ago
Chembio Diagnostics to Report Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019
Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the fourth quarter and full year 2018 after the close of trading on Thursday, March 7, 2019. Chembio Diagnostics, Inc. is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. The Company’s patented DPP technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in approximately 15 minutes.
- GlobeNewswire•3 months ago
Chembio Diagnostics to Participate in the BTIG Medical Technology, Life Science and Diagnostic Tools Conference
MEDFORD, N.Y., Feb. 19, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today the.
- Simply Wall St.•3 months ago
Do Insiders Own Shares In Chembio Diagnostics, Inc. (NASDAQ:CEMI)?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you want to know who reallyRead More...
- GlobeNewswire•4 months ago
Chembio Diagnostics Reports Preliminary Fourth Quarter and Full Year 2018 Revenue
Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today preliminary estimates of revenue for the fourth quarter and full year 2018, as well as long-term strategic targets. Revenue for the fourth quarter of 2018 is expected to be between $7.3 million and $7.6 million, an increase of approximately 22% to 27% compared to the fourth quarter of 2017. As a result, there is a possibility that final revenue results will not be within the ranges Chembio currently estimates. The company undertakes no responsibility to update its revenue outlook.
- GlobeNewswire•4 months ago
Chembio Diagnostics Announces 2019 Analyst and Investor Meeting
MEDFORD, N.Y., Jan. 17, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it.
- GlobeNewswire•5 months ago
Chembio Diagnostics Receives CE Mark for Point-of-Care Diagnostic Test Developed in Collaboration with AstraZeneca
MEDFORD, N.Y., Jan. 07, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that it.
- Simply Wall St.•5 months ago
Chembio Diagnostics, Inc.’s (NASDAQ:CEMI) Path To Profitability
Chembio Diagnostics, Inc.'s (NASDAQ:CEMI): Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or monitor diseases. With the latest Read More...
- GlobeNewswire•6 months ago
Chembio’s French Partner AAZ-LMB Wins Prix Galien International for Best Medical Technology with autotest VIH®
MEDFORD, N.Y., Dec. 06, 2018 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that its.
- Zacks Small Cap Research•6 months ago
CEMI: Record YTD Revenue, Margin Improvement Should Soon Follow
Chembio (CEMI) reported financial results for their third quarter ending September 30, 2018. Q3 made it three-for-three with us substantially underestimating product and total revenue every quarter so far in 2018. While it is unclear exactly what is catalyzing product revenue or where we’re missing, recently secured contracts (such as that with Bio-Manghinos) and international tenders (including the $15.8M tender from Ethiopia) are undoubtedly significant contributors to the record YTD revenue.
- Thomson Reuters StreetEvents•6 months ago
Edited Transcript of CEMI earnings conference call or presentation 8-Nov-18 9:30pm GMT
Q3 2018 Chembio Diagnostics Inc Earnings Call
- GlobeNewswire•6 months ago
Factors of Influence in 2018, Key Indicators and Opportunity within Sun Hydraulics, FIS, TRACON Pharmaceuticals, Kona Grill, Endava PLC Sponsored ADR, and Chembio Diagnostics — New Research Emphasizes Economic Growth
NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•6 months ago
Chembio Ebola Virus Diagnostic Test Receives U.S. FDA Emergency Use Authorization
Chembio Diagnostics, Inc. (CEMI), a leading point-of-care ("POC") diagnostics company focused on infectious diseases, today announced the receipt of U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for its DPP® Ebola Antigen System for use with human capillary “fingerstick” whole blood, EDTA venous whole blood, and EDTA plasma. The DPP® Ebola Antigen System includes the DPP® Ebola Assay and DPP® Micro Reader.
